Clinical Trial Search

Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…

Primary: 24 Hour Proteinuria — 3.6; 3.8; 2.2; 3.0 g/day

Primary: Part A: Change From Baseline in Proteinuria at Week 48 — -0.1364; 0.3560; 0.3430; -2.0347 ratio

Primary: Number of Participants With Adverse Events — 0; 11; 60 Participants

Primary: Change in Urine MCP1/Cr Levels — 5.57; 2.89 ng/mg

Primary: Cohort A: Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) — 0.55 ratio — p=0.0003

Primary: Randomized Controlled Period: Change From Baseline in Log-Transformed Urine Protein-to-Creatinine Ratio (uPCR) at Week 26 — -1.114; 0.029 log (uPCR) — p=<0.0001

Primary: Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks — 1; 1; 2; 1 participants — p=0.9074

Primary: Decrease in GFR During Treatment Period — -0.45 ml/min/1.73 m2 — p=<0.01

Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants

Primary: Focal Segmental Glomerulosclerosis Permeability Factor (FSPF) — 0.69; 0.35 Palb — p=0.009

Primary: Number of Participants With a Reduction in Proteinuria at 6 Months by > 50% of the Value at Screening AND Stable GFR Defined as Greater Than 75 ml/Min/1.73m2 in Those…

Primary: Number of Treatment-Emergent Adverse Events — 5 Serious Adverse Events

Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants

Primary: Doubling of Interstitium or Any ESRD — 6; 12 Participants

Primary: Change From Baseline to Week 26 in the C3G Histologic Index for Disease Activity - Subjects With Elevated C5b-9 — -0.9; -1.0 score on a scale — p=0.9670

Primary: Number of Patient Who Gained Remission From the Nephrotic Syndrome — 8; 8 Participants — p=0.7

Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g

Primary: Change From Baseline In Composite Biopsy Score At Week 28 — 11.7; 9.3; 9.2; 10.7 score on a scale

Primary: Percent Change in Urine Protein/Creatinine (Up/C) — -44.8; -18.5; -47.4; -33.1 percent change

Primary: Impact on the Trajectory of Serum and Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) Following Administration — -27.76; -11.11; -11.84; -8.23 ng/mL

Primary: Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12 — 48.9; 16.0; 38.5; 11.4 Predicted percentage of…

Primary: Change From Baseline in UPCR at Week 12 — 0.83; 1.02; 1.12; 0.87 g protein/g creatinine — p=0.1924

Primary: Percentage of Participants in Renal Response at Day 113 — 0.0; 7.7; 12.5; 33.3 Percent of Participants

Primary: Change in 24 Hour Creatinine Clearance — 41.0 mL/min/SA — p=0.072

Primary: Change in Proteinuria — 4.56; 1.36 ratio

Primary: Percentage of Complete Remission — 4; 3 Participants

Primary: Change in Proteinuria at 12 Months — 3; 3; 1; 2 participants

Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04

Primary: Number of Patients With Prevention of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) After Kidney Transplant — 1 Participants